"Factor VIIa" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Activated form of factor VII. Factor VIIa activates factor X in the extrinsic pathway of blood coagulation.
| Descriptor ID |
D015942
|
| MeSH Number(s) |
D08.811.277.656.300.760.300 D08.811.277.656.959.350.300 D12.776.124.125.325.300 D23.119.325.300
|
| Concept/Terms |
Factor VIIa- Factor VIIa
- Coagulation Factor VIIa
- Factor VIIa, Coagulation
- Blood Coagulation Factor VII, Activated
- Factor VII, Activated
- Activated Factor VII
- Factor 7A
- Factor Seven A
|
Below are MeSH descriptors whose meaning is more general than "Factor VIIa".
Below are MeSH descriptors whose meaning is more specific than "Factor VIIa".
This graph shows the total number of publications written about "Factor VIIa" by people in this website by year, and whether "Factor VIIa" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 1 | 0 | 1 |
| 1995 | 1 | 0 | 1 |
| 1997 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2006 | 3 | 0 | 3 |
| 2007 | 2 | 1 | 3 |
| 2008 | 4 | 0 | 4 |
| 2010 | 4 | 0 | 4 |
| 2013 | 1 | 1 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2021 | 0 | 2 | 2 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Factor VIIa" by people in Profiles.
-
Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors. Haemophilia. 2022 Jul; 28(4):548-556.
-
The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors. Haemophilia. 2021 Nov; 27(6):921-931.
-
PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors. Haemophilia. 2021 Nov; 27(6):911-920.
-
Prohemostatic Activity of Factor X in Combination With Activated Factor VII in Dilutional Coagulopathy. Anesth Analg. 2019 08; 129(2):339-345.
-
Coagulation Management During Liver Transplantation: Use of Fibrinogen Concentrate, Recombinant Activated Factor VII, Prothrombin Complex Concentrate, and Antifibrinolytics. Semin Cardiothorac Vasc Anesth. 2018 Jun; 22(2):164-173.
-
Impact on postoperative bleeding and cost of recombinant activated factor VII in patients undergoing heart transplantation. Ann Card Anaesth. 2016 Jul-Sep; 19(3):418-24.
-
In vitro effects of recombinant activated factor VII on thrombin generation and coagulation following inhibition of platelet procoagulant activity by prasugrel. Thromb Res. 2013 Jul; 132(1):106-11.
-
Three-factor prothrombin complex concentrate and hemostasis after high-risk cardiovascular surgery. Transfusion. 2013 Apr; 53(4):920-1.
-
Prothrombin complex concentrate versus recombinant factor VIIa for reversal of hemodilutional coagulopathy in a porcine trauma model. J Trauma. 2010 May; 68(5):1151-7.
-
Changing from aprotinin to tranexamic acid results in increased use of blood products and recombinant factor VIIa for aortic surgery requiring hypothermic arrest. J Cardiothorac Vasc Anesth. 2010 Dec; 24(6):959-63.